Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 439 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Excretion Clear all

Conditions: Non-valvular Atrial Fibrillation, Stroke, Systemic Embolism
Interventions: Experimental: Laminar Left Atrial Appendage Closure System, Active Comparator: WATCHMAN / Amulet; Device
Lead sponsor: Jaguar LAA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more

Conditions: Healthy
Interventions: Samidorphan IV, [14c]-Samidorphan sublingual, [14c]-Samidorphan oral; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Nocturnal Enuresis, Anemia, Sickle Cell
Interventions: Desmopressin; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 8 Years to 21 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Healthy Volunteers, Mass Balance Study
Interventions: AZD3293; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Cystinuria
Interventions: Bucillamine; Drug
Lead sponsor: Revive Therapeutics, Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Birmingham, Alabama • Boston, Massachusetts • New York, New York + 2 more

Conditions: Healthy Volunteers
Interventions: TAK-906 Oral Capsule, [14C]-TAK-906 Intravenous Infusion, [14C]-TAK-906 Oral Solution; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Bacterial Infections, Wounds
Interventions: Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R), Placebo, complex gel formulation without Vancomycin; Drug
Lead sponsor: Robert S Berman MD; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2024
U.S. locations: 1
States / cities: Jupiter, Florida

Conditions: Metabolism and Excretion
Interventions: E2006; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Osteopenia
Interventions: veverimer daily, veverimer every other day, Placebo; Drug · Other
Lead sponsor: Tufts Medical Center; Other
Eligibility: 50 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Participants
Interventions: [14C]-darigabat; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pharmacokinetics, Metabolism
Interventions: Lurasidone; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Eosinophilic Esophagitis
Interventions: Diet Change; Other
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 1 Year to 18 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Encopresis, ASD
Interventions: Glycerin Suppository, Behavioral strategies; Drug · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 5 Years to 12 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy Volunteers
Interventions: [14C]-TVB-2640; Drug
Lead sponsor: Sagimet Biosciences Inc.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Kidney Transplant Dysfunction
Interventions: Not listed
Lead sponsor: Northwell Health; Other
Eligibility: 3 Years to 18 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Healthy Volunteers
Interventions: [14C]-olinciguat; Drug
Lead sponsor: Cyclerion Therapeutics; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Participants
Interventions: BMS-986166, Bisacodyl; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteer
Interventions: [14C]-EDG-7500; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prematurity, Respiratory Distress Syndrome, Apnea of Prematurity
Interventions: continuous positive airway pressure, nasal intermittent positive pressure ventilation; Other
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: Up to 6 Months
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Nasal Obstruction, Chronic Rhinitis
Interventions: Oxymetazoline + Triamcinolone; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy Volunteer Study
Interventions: AT-527 (R07496998); Drug
Lead sponsor: Atea Pharmaceuticals, Inc.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Volunteers
Interventions: [14C]-Fosgonimeton; Drug
Lead sponsor: LeonaBio; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hypertension
Interventions: baxdrostat; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: [14C]-JNT-517; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination

A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male Volunteers

Desmopressin for Bedwetting in Children With SCD

A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293

Bucillamine Phase 2 Trial in Patients With Cystinuria

Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants

Effects of MRSA Bactericidal Gel To Promote Healing and Eliminate MRSA in cSSTI Vancogel(TM)

An Open-label, Single-dose Study to Determine the Metabolism and Excretion of [14C]E2006 in Healthy Male Subjects

Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia

A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male Participants

RI-AME Study OF [ISOTHIAZOLYL-3-14C]-LURASIDONE

Cow's Milk Elimination for Treatment of Eosinophilic Esophagitis

Comprehensive Toileting Program

Open-label Study of the Absorption, Metabolism, and Excretion of [14C]TVB-2640 Following a Single Oral Dose in Healthy Male Subjects

Urinary Kidney Injury Molecule-1 (KIM-1) Excretion As Biomarker for Injury in Kidney Transplant Recipients

A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Olinciguat in Healthy Male Volunteers

A Study to Evaluate the Drug Levels of BMS-986166 in Healthy Male Participants

A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500

CPAP vs.Unsynchronized NIPPV at Equal Mean Airway Pressure

Steroid Treatment for Elimination of Rebound Obstruction From Intranasal Decongestants

Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)

A Study of the Absorption, Metabolism, and Excretion of [14C]-Fosgonimeton (ATH-1017)

Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat

How [14C]-JNT-517 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Male Participants